Sanders Morris Harris LLC Sells 190 Shares of Johnson & Johnson (NYSE:JNJ)

Sanders Morris Harris LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,945 shares of the company’s stock after selling 190 shares during the period. Sanders Morris Harris LLC’s holdings in Johnson & Johnson were worth $1,126,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Putnam Investments LLC boosted its holdings in shares of Johnson & Johnson by 0.3% in the 4th quarter. Putnam Investments LLC now owns 624,978 shares of the company’s stock valued at $97,959,000 after buying an additional 2,128 shares in the last quarter. Kestra Advisory Services LLC boosted its stake in Johnson & Johnson by 3.9% in the 4th quarter. Kestra Advisory Services LLC now owns 328,605 shares of the company’s stock worth $51,505,000 after purchasing an additional 12,265 shares in the last quarter. Waverly Advisors LLC boosted its stake in Johnson & Johnson by 45.9% in the 4th quarter. Waverly Advisors LLC now owns 77,334 shares of the company’s stock worth $12,121,000 after purchasing an additional 24,318 shares in the last quarter. Pinnacle Holdings LLC raised its position in Johnson & Johnson by 5.4% during the 4th quarter. Pinnacle Holdings LLC now owns 13,265 shares of the company’s stock worth $2,079,000 after buying an additional 685 shares during the last quarter. Finally, Pathstone Holdings LLC purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $55,434,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Royal Bank of Canada lifted their target price on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $173.43.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $161.00 on Thursday. The stock has a 50 day moving average price of $162.65 and a 200 day moving average price of $154.41. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $387.48 billion, a price-to-earnings ratio of 10.02, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.80 earnings per share. Research analysts predict that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.